Education and Training
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: bevacizumab
- drug: FOLFIRI
- drug: FOLFOX
- drug: Vismodegib
Eligibility
This study only enrolled participants who took part in previous studies of vismodegib
conducted by Genentech.
Inclusion Criteria:
- Completed vismodegib treatment within 2-4 weeks in a Genentech-sponsored parent study
or continued to receive vismodegib at the time the Genentech-sponsored parent study
closed.
- Expectation by the investigator that the participant may continue to benefit from
additional vismodegib treatment.
Exclusion Criteria:
- Intervening anti-tumor therapy not specified in the parent study (ie,
non-protocol-specified chemotherapy, other targeted therapy, radiation therapy, or
photodynamic therapy).
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061
Not Recruiting